P-169: CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY

Introduction: The advances in the management of multiple myeloma (MM) have yielded improved outcomes. Both the use of novel therapies and consolidation with autologous stem-cell transplantation have demonstrated superior overall response and progression-free survival rates. However, these are not readily available in most Latin American countries. Here, we aim to characterize the clinico-epidemiological features, treatment and outcome patterns of newly diagnosed MM patients in a referral center in Paraguay.

Methods: We conducted a retrospective observational cohort study. Data were collected from clinical records, classified according to the International Staging System (ISS) and stage of the disease. Clinical and epidemiological characteristics were analyzed as well as access to first-line transplantation in newly diagnosed MM patients diagnosed from 2018 to 2022.

Results: We included 127 patients aged 65 years and younger. Most patients were male (52%), with IgG immunoglobulin subtype (69%), and the most frequently with Kappa light chain (59%). According to the ISS classification, 40% of the patients were ISS2 at diagnosis, 34% ISS1 and 26% ISS3. Stage at diagnosis were: IIA in 32% of patients, IIB 24%, IIIA 20%, IIIB 13% IA 10% and IB 1%. Initial clinical presentations included anemia in 75% of the patients, 53% had renal failure, and 26% had bone lesions. The first line scheme in patients without renal failure was VTD (Bortezomib, Thalidomide, Dexamethasone), and patients with renal failure received CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone). About 58% of the patients were able to access a transplant in the first line of treatment. The patients who did not have access to transplantation were due to progression during first line or death due to infectious causes.

Conclusions: To our knowledge, this is the first study that characterizes Paraguayan patients with newly diagnosed MM, which also allows us to assess the number of patients accessing a standard treatment that achieves adequate responses to be able to undergo Autologous Bone Marrow Transplantation (BMT).